Open Access

Prognostic implication of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma: a tissue microarray study

  • Zheng Liu1,
  • Qiang Fu1,
  • Jiaju Lv1Email author,
  • Facheng Wang1 and
  • Kejia Ding1
Contributed equally
Journal of Experimental & Clinical Cancer Research200827:51

https://doi.org/10.1186/1756-9966-27-51

Received: 15 September 2008

Accepted: 15 October 2008

Published: 15 October 2008

Abstract

Background

p27Kip1 plays a major role as a negative regulator of the cell cycle. The regulation of p27Kip1 degradation is mediated by its specific ubiquitin ligase subunits S-phase kinase protein (Skp) 2 and cyclin-dependent kinase subunit (Cks) 1. However, little is known regarding the prognostic utility of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma.

Methods

Immunohistochemistry was performed for p27Kip1, Skp2 and Cks1 in tissue microarrays of 482 renal cell carcinomas with follow-up. The data were correlated with clinicopathological features. The univariate and multivariate survival analyses were also performed to determine their prognostic significance.

Results

Immunoreactivity of p27Kip1, Skp2 and Cks1 was noted in 357, 71 and 82 patients, respectively. Skp2 and Cks1 expression were not noted in chromophobe cancers. A strong correlation was found between Skp2 and Cks1 expression (P < 0.001), both of which were inversely related to p27Kip1 levels (P = 0.006 and P < 0.001), especially in primary and clear-cell cancers. Low p27Kip1 expression and Skp2 expression were correlated with larger tumor size and higher stage, as well as tumor necrosis. Cks1 expression was only correlated with tumor size. In univariate analysis, low p27Kip1 expression, Skp2 and Cks1 expression were all associated with a poor prognosis, while in multivariate analysis, only low p27Kip1 expression were independent prognostic factors for both cancer specific survival and recurrence-free survival in patients with RCC.

Conclusion

Our results suggest that immunohistochemical expression levels of p27Kip1, Skp2 and Cks1 may serve as markers with prognostic value in renal cell carcinoma.

Background

Renal cell carcinoma (RCC) is the most common malignancy in adult kidney, with 30,000 new cases per year in the U.S. and 20,000 cases in the European Union [1]. Over the last 20 years, the incidence of renal cell carcinoma in the two regions has increased by 30% [2]. Though the number of RCC cases in Asian is still unknown, publications in this regard have suggested a tendency of annual increase. In light of this situation, predicting the prognosis of RCC patients becomes essential for planning and optimizing treatment strategies. The prognosis of RCC is usually affected by such factors as performance status, pathological stage, tumor size, nuclear grading, and microscopic tumor necrosis. Yet, the accuracy of the traditional clinical and histologic markers is still unsatisfactory in certain clinical settings. There lies the possibility that biologic markers, which have associated with tumor progression, could serve as accurate prognostic markers or targets for specific intervention.

As the alteration of cell cycle is a hallmark of cancer, proteins that are intimately involved in cell cycle regulation are of particular interest. The cell cycle progression is largely dependent on cyclins and cyclin-dependent kinases (Cdks) [3]. Cdks are regulated by Cdk inhibitors, including the INK4 family and the Cip/Kip family. The p27, a member of the latter (p27/Kip1), negatively regulates cell cycle by inactivating cyclin-CDK complex and preventing the transition from G1 to S phase. The degradation of p27 stimulates the activity of Cdk2/cyclin E and Cdk2/cyclin A to promote cell proliferation. Recent evidence also suggests that p27Kip1 is a putative tumor suppressor, thus the loss of p27Kip1 may lead to the uncontrolled proliferation of malignant cells [4]. Recently, reduced expression of p27Kip1 protein has been proved to be highly associated with tumor progression and poor prognosis in various malignant diseases [5]. However, downregulation of p27Kip1 mRNA is rarely observed in human cancers [6]. Instead, the decrease in p27Kip1 levels results mainly from ubiquitin-mediated proteolysis, regulated by the F-box protein SKP2(S-phase kinase-associated protein 2), and its cofactor, Cks1 [7]. SKP2 is an important component of the Skp1-Cullin-F-box protein (SCF) complex, which functions as the main rate-limiting regulator for the degradation of p27Kip1. Hence, overexpression of Skp2 may lead to cell-cycle progression. Recent studies have also found that Skp2 may modulate invasion of cancer cells independent of p27 degradation [8]. Cks1 is a member of the highly conserved Cks/Suc1 proteins family, which confers an allosteric change in Skp2 to increase its affinity to phosphorylated p27Kip1 substrate [9, 10]. Therefore, p27Kip1 degradation is dependent upon the accumulation of Skp2 and Cks1 as well as the rise in cyclin E. Recently, the expression levels of p27Kip1, Skp2 and Cks1 were shown to be highly associated with prognosis in a variety of cancers [1013].

To date, very few studies have addressed the prognostic role of P27Kip1and Skp2 in renal cell carcinoma. And no study has elucidated the roles of Cks1 in RCCs. By using tissue microarray, we therefore aimed at analyzing the immunohistochemical expression patterns of p27Kip1, Skp2, and Cks1 proteins, and their associations with clinical and pathologic factors, as well as the prognostic implications.

Methods

Patients and specimens

Our study cohort consisted of 482 patients who underwent radical or partial nephrectomy for RCC at the Shandong Provincial Hospital between 1993 and 2005. As approved by the ethical committees of Shandong Provincial Hospital, Formalin-fixed and paraffin-embedded specimens of these cases were chosen for analysis. Clinical data were recorded, including age, sex, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) score. Pathological variables were re-evaluated by 2 pathologists separately, including pT stage, Fuhrman grade and histological subtype. Patients were staged according to the 1997 staging system of the Union International Contre le Cancer (UICC) and American Joint Committee on Cancer (AJCC) [14]. The histological subtypes were stratified using Heidelberg classification [15] and the nuclear grade of tumors was determined by e Fuhrman grading scheme [16]. Performance status was determined using the Eastern Cooperative Oncology Group Performance Score (ECOG-PS) scale. The patients consisted of 329 men and 153 women, aging 19 to 94 years old, with a mean age of 62.1. There were 384 conventional, 81 papillary, and 17 chromophobe cases of RCCs respectively. 45 patients had distant metastases (to the lung in 12 patient, bone in 4 patients, the lymph nodes in 14 patients, gastrointestinal tract in 7 patients, soft tissue in 2 patients and adrenal gland in 6 patients) at the time of surgery. 324 (67.2%) tumors were discovered incidentally, 126 (26.1%) were locally symptomatic and 32 patients (6.6%) had systemic disease symptoms. The median period of follow-up for all patients was 62 months, ranging from 13 to 185 months.

Construction of tissue microarray blocks and immunohistochemistry

For immunohistochemical evaluation, tissue microarrays were constructed using a manual tissue arrayer with accessory (Beecher, Silver Spring, MD). 3 cylindrical core biopsies (0.6 mm in diameter) were taken from different sites of each tumor and precisely arrayed in a recipient paraffin tissue microarray block. 10 specimens of non-neoplastic renal tissue resected from adjacent regions of renal cell carcinoma were also analysed for comparison.

The procedures of immunohistochemical studies were performed as described previously [13]. In brief, 4-mm tissue microarray sections were incubated with the mouse monoclonal antibodies targeting Skp2 (1:100, Zymed), Cks1 (1:250, Zymed), p27Kip1 (1:50, Santa Cruz), using an automated immunostainer(Leica AutoStainer XL,). Binding of the primary antibody was assessed using the DAKO EnVision kit (DAKO Corp.), and the hematoxylin served as counterstain. Incubation without the primary antibody was used as a negative control.

Assessment of immunohistochemical staining

Two pathologists, blinded to the clinicopathological data and patients' outcomes, independently evaluated immunoreactivity of the tissue microarray slides. Discrepancies were resolved by simultaneous re-examination of the slides by both investigators. Immunostaining was evaluated by recording the percentage of cells staining and scoring the area of maximum staining on a 4-point scale, with 0 representing no staining and 3 representing the highest staining. The results from 3 cores in the same patient were averaged to obtain a mean value for subsequent statistical analysis. According to the median percentage of positive cells for each antibody, the protein expression results were classified into 3 groups: Negative group; Low group (less than the median value) and High group (greater than the median value). The median values were: 40% for p27, 10% for Skp2, and 20% for Cks1. As described in previous studies [13], the expressions of Skp2 and Cks1 was further stratified as either positive or negative (Low+High group versus Negative group), while the p27Kip1 expression was further classified as high expression (High group) and low expression (Negative+Low group).

Statistical analysis

Statistical data analyses were performed using SPSS 11.0 statistical software package (SPSS Inc., Chicago, IL). First, the associations among Skp2, Cks1, p27Kip1 and clinicopathological factors were explored using χ2 test or Fisher's exact test as appropriate. Correlations between variables were tested according to the Spearman correlation test. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed by Kaplan-Meier curves. The prognostic role of different parameters in the disease recurrence and patient death was analyzed with the log-rank test. For multivariate testing, a stepwise forward Cox's proportional hazards regression model was performed to define the risk factors for tumor recurrence and patient death. P values less than 0.05 were considered significant. Two-sided tests were used throughout all the analyses.

Results

Immunohistochemical expression and its correlation with clinicopathological variables

Representative examples of reactivity for p27Kip1, Skp2, and Cks1 are shown in Figure 1.
Figure 1

Expression of p27 Kip1 , Skp2 and Cks1. The proteins showing null/low or high levels of expression with nuclear pattern. (immunohistochemical staining; original magnification ×200; scale bar, 200 μm).

In nonneoplastic renal tissue, the distal tubules, glomerular epithelial cells, and pelvic urothelium showed strong nuclear p27Kip1 immunoreactivity but lacked immunoreactivity for Skp2 and Cks1.

The protein expression and clinicopathological data of the patients are summarized in Table 1. As shown in Table 1, Skp2, Cks1, and p27Kip1 expressions were not associated with patients' age or gender, as well as the ECOG-PS. In addition, none of the protein expression was associated with the grade.
Table 1

Expression of p27Kip1, Skp2, and Cks1 in relation to clinicopathological parameters

  

P27

Skp2

Cks1

Variables

No.

Low

High

p-value

N

P

p-value

N

P

p-value

Age, years

          

Mean

 

62.5

61.3

0.904

62.0

65.1

0.723

60.0

62.3

0.630

Gender

          

Men

329

213

116

 

281

48

 

272

57

 

Women

153

101

52

0.785

130

23

0.898

120

33

0.266

Metastasis

          

Negative

437

279

158

 

376

61

 

359

78

 

Positive

45

35

10

0.062

35

10

0.136

33

12

0.148

Histology

          

Clear cell

384

239

145

 

316

68

 

302

82

 

Papillary

81

61

20

 

78

3

 

73

8

 

Chromophobe

17

14

3

0.008a

17

0

<0.001a

17

0

0.003a

pT stage

          

1

255

141

114

 

243

12

 

217

38

 

2

103

78

25

 

83

20

 

78

25

 

3+4

124

95

29

0.002b

85

39

<0.001b

97

27

0.304b

Tumor size

          

≤ 7.0

324

188

136

 

298

26

 

273

51

 

>7.0

158

126

32

<0.001

113

45

<0.001

119

39

0.018

Grade

          

1

78

46

32

 

68

10

 

60

18

 

2

250

159

91

 

215

35

 

201

49

 

3

121

86

35

 

102

19

 

103

18

 

4

33

23

10

0.075c

26

7

0.361c

28

5

0.149c

Necrosis

          

Absent

432

271

161

 

376

56

 

352

80

 

Present

50

43

7

0.001

35

15

0.001

40

10

0.799

ECOG-PS

          

= 0

388

250

138

 

335

53

 

313

75

 

>0

94

64

30

0.505

76

18

0.178

79

15

0.452

Note: N indicates negative; P indicates positive;

a Histology, clear cell vs. others.

bStage, Stages I and II vs. Stages III and IV.

c Grade, Grade1/2 vs. Grade3/4.

P27Kip1 expression was noted in 357 cases (74%), and high expression of p27Kip1 was identified in 168 cases (37%). The expression of p27Kip1 was significantly higher in clear-cell RCC compared with other histological types (P = 0.008). Furthermore, the expression significantly decreased with increasing tumor stage (P = 0.002) and tumor size (P < 0.001). In addition, the p27Kip1 was also significantly downregulated in cases with tumor necrosis (P = 0.001). And the expression was not significantly different between primary and metastatic tumors (P = 0.062).

Skp2 expression was noted in 68 of 384 (18%) clear cell and 3 of 81 (4%) papillary tumors, but none of chromophobe tumors. Skp2 expression was significantly correlated with tumor stage (P < 0.001) and tumor size (P < 0.001), as well as tumor necrosis (P = 0.001). But Skp2 expression was not significantly different between primary and metastatic tumors (P = 0.136).

Cks1 expression was similar to Skp2, noted only in 82 of 384 (21%) clear cell and 8 of 81(10%) papillary tumors. Among various clinicopathological variables, the expression of Cks1 was only correlated with tumor size (P = 0.018).

Associations among P27Kip1, Skp2 and Cks1 protein expression

A strong correlation was found between Skp2 and Cks1 expression (P < 0.001), both of which were inversely related to p27Kip1 levels (P = 0.006 and P < 0.001). A further test was performed between patients with different metastatic status and histologic types. In primary RCCs, relation between Skp2 and Cks1 expression and their inverse relations to p27Kip1 levels are statistically significant (P < 0.001, P = 0.001 and P = 0.001, respectively). But in metastatic RCCs, no correlation was found: 5 Skp2-positive RCCs showed Cks1 positive expression, while 5 Skp2-positive and 10 Cks1-positive RCCs showed low p27 expression, with a P value of 0.058, 0.179 and 0.893, respectively.

In clear-cell RCCs, the correlation among the protein expression was the same as that in the whole patients. But in papillary tumors, only the inverse associations between p27Kip1 and Cks1 was statistically significant (P = 0.027).

Survival analysis

At the end of follow-up, 131 patients died due to cancer progression, 36 patients died of unrelated causes, and 128 patients developed disease recurrence.

In the univariate analysis, the Kaplan-Meier survival curves showed that high Skp2 and Cks1 expression and low p27Kip1 expression related to a poor survival with statistical significance, regardless of endpoints (Table 2, Fig. 2). The Cox's proportional hazards regression model proved that tumor stage, tumor size and low p27Kip1 expression or lack of p27Kip1 immunoreactivity were independent prognostic factors for different endpoints in patients with RCC (Table 2).
Figure 2

Kaplan-Meier survival curves according to protein expression of p27 Kip1 , Skp2 and Cks1. Cancer-specific survival of patients with RCC were significantly associated with the expression levels of p27Kip1 (A), Skp2(C), Cks1(E); Recurrence-free survival were significantly associated with the expression levels of p27Kip1 (B), Skp2(D), Cks1(F).

Table 2

Univariate and Multivariate Survival Analysis

 

P value on CSS

P value on RFS

Variables

Univariatea

Multivariateb

Univariatea

Multivariateb

Age

0.556

0.236

0.522

0.413

Gender

0.598

0.326

0.885

0.590

TNM stage

<0.001

<0.001

<0.001

<0.001

Tumor size

<0.001

<0.001

<0.001

<0.001

Grade

0.388

0.078

0.085

0.219

Histology

0.859

0.396

0.704

0.730

ECOG-PS

0.046

0.874

0.259

0.427

Necrosis

<0.001

0.117

<0.001

0.242

p27Kip1

<0.001

0.003

<0.001

0.002

Skp2

<0.001

0.360

0.001

0.966

Cks1

0.002

0.110

0.029

0.482

Note: OS: overall survival; CSS: cancer-specific survival; RFS: recurrence-free survival.

a Statistical analyses were performed by the log-rank test.

b Statistical analyses were performed by Cox proportional-hazards regression model.

Discussion

To our knowledge, the current study presents the largest samples for investigating the expression of p27Kip1 and its interacting cell cycle regulators: Skp2 and Cks1. This is also the first article to analyse Cks1 expression in renal cell carcinoma, with respect to possible associations with clinicopathological data as well as patients' prognosis. Furthermore, for the first time, the possible relation between levels of p27Kip1 and of its specific ubiquitin ligase subunit Skp2 and Cks1 was assessed in renal cell carcinoma.

p27Kip1 is a member of the Cip/Kip family of CDK inhibitory proteins and serves as an important regulator for both cellular proliferation and tissue differentiation. Till now, the significant association between low p27Kip1 expression and adverse pathologic features or poor survival has been found in patients with a variety of neoplasms, including carcinoma of the gastrointestinal system [17], prostate [18, 19], breast [11], and lung [12]. However, previous studies on p27Kip1 expression in RCCs presented contradictory results. The low p27Kip1 expression was found to be related to high-stage and high-grade RCCs by Langner C et al. [13] and Hedberg et al. [20]. Yet, other studies reported that the p27Kip1 level only was only related to the TNM stage [21] or no associations at all [22]. Furthermore, although Hedberg et al. [20] reported the different p27Kip1 expression patterns among various histologic subtypes, such results were not confirmed in other studies [13]. In our study, the expression of p27Kip1 was significantly higher in clear-cell RCC compared with other histologic types and inversely related to TNM stage and tumor size. And no association between p27Kip1 expression and metastatic status confirms the result in previous study for RCC [13] and other carcinomas [23].

More intriguingly, the controversy regarding association between grade and p27Kip1 expression arised not only in RCCs, but also in many other cancers [24, 25]. This discrepancy might be ascribed to the following reasons. First, the assessment of the grade may be highly observer dependent. Second, insufficient formalin fixation in some specimens may result in artificial reduced labeling of p27Kip1 in TMA. More likely, the root cause might stem from the complex regulatory mechanisms of p27Kip1 abundance. For instance, a new ubiquitin ligase for p27Kip1 has recently been identified, which is a member for Skp2-independent down-regulation of p27Kip1 at the G0–G1 transition [26].

The regulation of p27Kip1 is mainly determined by its rate of degradation rather than by transcription or translation. Recent studies indicate that Skp2 and Cks1, the cell-cycle regulatory proteins, play essential roles in the degradation of p27Kip1. Skp2 is an ubiquitin ligase responsible for targeting P27Kip1 to the proteasome and Cks1 is an essential cofactor for efficient Skp2 dependent p27Kip1 ubiquitination. Several studies have provided evidence that both the Skp2 and Cks1 may have important roles in the development of tumor aggressiveness and its expression may be used as an independent prognostic factor for survival in various carcinomas[12, 13, 17, 27]. In this study, Skp2 expression was found to be significantly correlated with advanced T stage, larger tumor size and necrosis, while Cks1 only correlated with tumor size. The results imply their importance in disease progression and confirm the previous studies. However, the different expression pattern among histologic types, such as no expression of Skp2 and Cks1 in chromophobe RCC, has never been previously reported. Thus, the expression of Skp2 and Cks1 combined with p27Kip1 could help to separate the chromophobe from the clear cell subtype.

As for the association among p27Kip1, Skp2 and Cks1, it is still in dispute [1013]. In this study, there was a significant positive correlation between SKP2 and CKS1 expression, as well as an inverse relationship between p27Kip1 and the 2 proteins. To examine whether other factors affected the association, we carried out further subanalysis dividing patients into subgroups based upon histologic subtypes and metastatic status. The correlation among these proteins was only found to be significant in primary and clear-cell RCCs. The observation may partially explain the current dispute, as the different samples used by different researchers. It also suggests that p27Kip1 downregulation may involve several pathways and occur through corresponding pathway in different status.

Consistent with previous studies [13, 2022], we found that TNM stage and tumor size were strong predictive prognostic markers in patients with RCC. With regard to prognostic significance of protein expression, our study also demonstrated that low p27Kip1 expression significantly correlated with a poor outcome. Although the Skp2 and Cks1 expression correlated within inferior CSS and DFS in our univariate analysis, it did not remain prognostically independent in multivariate comparison.

Conclusion

In summary, our study suggests that immunohistochemical expression levels of p27Kip1, Skp2 and Cks1 may serve as markers with prognostic implication. The inverse association between p27Kip1 and Skp2 or Cks1 indicates the important roles of Skp2 and Cks1 in targeting the destruction of p27Kip1, and these regulatory proteins may well be considered as novel targets of therapeutic intervention in RCC in the future.

Notes

Declarations

Acknowledgements

This work was supported by fund from Department of Science & Technology of Shandong Province, China (GG3202194).

Authors’ Affiliations

(1)
Department of Urology, Shandong Provincial Hospital, Shandong University

References

  1. Kirkali Z, Tuzel E, Mungan MU: Recent advances in kidney cancer and metastatic disease. BJU Int. 2001, 88: 818-824. 10.1046/j.1464-4096.2001.02442.x.View ArticleGoogle Scholar
  2. Patard JJ, Tazi H, Bensalah K: The changing evolution of renal tumors: a single center experience over a two-decade period. Eur Urol. 2004, 45: 490-494. 10.1016/j.eururo.2003.12.015.View ArticleGoogle Scholar
  3. Grana X, Reddy FP: Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDK), growth suppressor genes and inhibitors (CKIs). Oncogene. 1995, 11: 211-219.Google Scholar
  4. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999, 154: 313-323.View ArticleGoogle Scholar
  5. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone or in combination, correlate with survival of young breast patients. Nat Med. 1997, 3: 222-225. 10.1038/nm0297-222.View ArticleGoogle Scholar
  6. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995, 269: 682-5. 10.1126/science.7624798.View ArticleGoogle Scholar
  7. Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI: A CDK-independent function of mammalian Cks1: targeting of SCF(SKP2) to the CDK inhibitor p27Kip1. Mol Cell. 2001, 7: 639-50. 10.1016/S1097-2765(01)00210-6.View ArticleGoogle Scholar
  8. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama T, Nakayama T, Mori M: Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002, 62: 3819-3825.Google Scholar
  9. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M, Hershko A: The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol. 2001, 3: 321-324. 10.1038/35060126.View ArticleGoogle Scholar
  10. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD: The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer. 2005, 103: 1336-1346. 10.1002/cncr.20917.View ArticleGoogle Scholar
  11. Slotky M, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, Hershko DD: The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res. 2005, 7: R737-744. 10.1186/bcr1278.View ArticleGoogle Scholar
  12. Yokoi S, Yasui K, Mori M, Iizasa T, Fujisawa T, Inazawa J: Amplification and overexpression of Skp2 are associated with metastasis of non-small-cell lung cancers to lymphnodes. Am J Pathol. 2004, 165: 175-180.View ArticleGoogle Scholar
  13. Langner C, vonWasielewski R, Ratschek M, Rehak P, Zigeuner R: Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch. 2004, 445: 631-6. 10.1007/s00428-004-1121-2.View ArticleGoogle Scholar
  14. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A: TNM staging of renal cell carcinoma: Workgroup No.3 – Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997, 80: 992-993. 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q.View ArticleGoogle Scholar
  15. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, Berg van den E, Zbar B: The Heidelberg classification of renal cell tumors. J Pathol. 1997, 183: 131-133. 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G.View ArticleGoogle Scholar
  16. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982, 6: 655-663.View ArticleGoogle Scholar
  17. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM, Hershko A: Inverse relation between levels of p27kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 2001, 91: 1745-1751. 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H.View ArticleGoogle Scholar
  18. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998, 159: 941-5. 10.1016/S0022-5347(01)63776-5.View ArticleGoogle Scholar
  19. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998, 58: 542-8.Google Scholar
  20. Hedberg Y, Ljungberg B, Roos G, Landberg G: Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer. 2003, 88: 1417-1423. 10.1038/sj.bjc.6600922.View ArticleGoogle Scholar
  21. Migita T, Oda Y, Naito S, Tsuneyoshi M: Low expression of p27kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 2002, 94: 973-979. 10.1002/cncr.10338.View ArticleGoogle Scholar
  22. Haitel A, Wiener HG, Neudert B, Marberger M, Susani M: Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology. 2001, 58: 477-481. 10.1016/S0090-4295(01)01188-8.View ArticleGoogle Scholar
  23. McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI, McLeod HL: Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res. 2000, 6: 1113-1118.Google Scholar
  24. Fromont G, Rouprêt M, Amira N, Sibony M, Vallancien G, Validire P, Cussenot O: Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol. 2005, 48: 764-70. 10.1016/j.eururo.2005.07.005.View ArticleGoogle Scholar
  25. Huang Hsuan-Ying, Kang Hong-Yo, Li Chien-Feng, Eng Hock-Liew, Chou Shih-Cheng, Lin Ching-Nan, Hsiung Ching-Yeh: Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res. 2006, 12: 487-498. 10.1158/1078-0432.CCR-05-1497.View ArticleGoogle Scholar
  26. Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI: Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004, 6: 1229-1235. 10.1038/ncb1194.View ArticleGoogle Scholar
  27. Masuda TA, Inoue H, Nishida K, Sonoda H, Yoshikawa Y, Kakeji Y, Utsunomiya T, Mori M: Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res. 2003, 9 (15): 5693-5698.Google Scholar

Copyright

© Liu et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement